SCHEMBL16486803

SCHEMBL16486803

Cc1cnn(Cc2ccc(C=O)cc2)c1

nearest known ligand 0.48

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 16/20 0.48
RAB9A P51151 1/20 0.44
DUSP3 P51452 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CYP2A6 P11509 1/20 0.42
KLK1 P06870 3/20 0.42
HSD17B10 Q99714 1/20 0.41
NR1I2 O75469 1/20 0.41
KCNH2 Q12809 1/20 0.41
GRM2 Q14416 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4769322 0.84 SMN1; SMN2 (0.51) KLKB1RAB9ADUSP3SMN1; SMN2L3MBTL1
SCHEMBL15759268 0.83 KLKB1 (0.51) KLKB1RAB9ADUSP3SMN1; SMN2L3MBTL1
SCHEMBL13813853 0.80 KCNH2 (0.53) KLKB1SMN1; SMN2HSD17B10KCNH2
SCHEMBL16246747 0.80 KLKB1 (0.49) KLKB1L3MBTL1KLK1HSD17B10
SCHEMBL17232474 0.80 KLKB1 (0.49) KLKB1L3MBTL1KLK1HSD17B10
SCHEMBL20056946 0.79 KLKB1 (0.49) KLKB1KLK1HSD17B10
SCHEMBL15033959 0.78 KLKB1 (0.51) KLKB1KLK1HSD17B10NR1I2KCNH2
SCHEMBL16246702 0.78 KLKB1 (0.48) KLKB1L3MBTL1KLK1HSD17B10
SCHEMBL13102481 0.78 KLKB1 (0.54) KLKB1L3MBTL1KLK1
SCHEMBL27239076 0.78 KLKB1 (0.65) KLKB1KLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220153724-A1 Inhibitors Of Plasma Kallikrein KALVISTA PHARMACEUTICALS LTD (GB) 2022-05-19 US disclosed
US-11242333-B2 Inhibitors of plasma kallikrein KALVISTA PHARMACEUTICALS LIMITED (GB) 2022-02-08 US disclosed
US-20190152950-A1 Inhibitors Of Plasma Kallikrein KALVISTA PHARMACEUTICALS LTD (GB) 2019-05-23 US disclosed
US-10221161-B2 Inhibitors of plasma kallikrein KALVISTA PHARMACEUTICALS LIMITED (GB) 2019-03-05 US disclosed
CN-105683179-B inhibitors of plasma kallikrein 卡尔维斯塔制药有限公司 2018-10-26 CN disclosed
EP-3033336-B1 INHIBITORS OF PLASMA KALLIKREIN KALVISTA PHARMACEUTICALS LTD (GB) 2018-05-30 EP disclosed
EP-3033336-A1 INHIBITORS OF PLASMA KALLIKREIN Kalvista Pharmaceuticals Limited (GB) 2016-06-22 EP disclosed
US-20160168123-A1 INHIBITORS OF PLASMA KALLIKREIN KALVISTA PHARMACEUTICALS LIMITED (GB) 2016-06-16 US disclosed
WO-2015022546-A1 INHIBITORS OF PLASMA KALLIKREIN KALVISTA PHARMACEUTICALS LIMITED (GB) 2015-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190152950-A1 Inhibitors Of Plasma Kallikrein KLKB1, SERPINB1, KLK5 KLKB1 1/4885RAB9A 1777/4885DUSP3 4144/4885
US-20220153724-A1 Inhibitors Of Plasma Kallikrein KLKB1, SERPINB1, KLK5 KLKB1 1/4885RAB9A 1777/4885DUSP3 4144/4885
US-11242333-B2 Inhibitors of plasma kallikrein KLKB1, SERPINB1, KLK5 KLKB1 1/4885RAB9A 1777/4885DUSP3 4144/4885
US-10221161-B2 Inhibitors of plasma kallikrein KLKB1, SERPINB1, KLK5 KLKB1 1/4885RAB9A 1777/4885DUSP3 4144/4885
US-20160168123-A1 INHIBITORS OF PLASMA KALLIKREIN KLKB1, SERPINB1, KLK5 KLKB1 1/4885RAB9A 1777/4885DUSP3 4144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.